Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study

키워드

참고문헌 (44)

1. Sung H, "Global cancer statistics 2020 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 71, pp.209~249 (2021)
2. Petrick JL, "International trends in hepatocellular carcinoma incidence, 1978-2012", Int J Cancer, 147, pp.317~330 (2020)
3. McGlynn KA, "Epidemiology of hepatocellular carcinoma", Hepatology, 73(Suppl 1(Suppl 1)), pp.4~13 (2021)
4. Sherif ZA, "Trends in the incidence of hepatocellular carcinoma in Washington DC : a single institutional cohort study(1959-2013)", J Natl Med Assoc, 113, pp.396~404 (2021)
5. Yang JD, "A global view of hepatocellular carcinoma : trends, risk, prevention and management", Nat Rev Gastroenterol Hepatol, 16, pp.589~604 (2019)
6. Global Burden of Disease Cancer Collaboration, "Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015 : a systematic analysis for the global burden of disease study", JAMA Oncol, 3, pp.524~548 (2017)
7. Yang JD, "Hepatocellular carcinoma : a global view", Nat Rev Gastroenterol Hepatol, 7, pp.448~458 (2010)
8. El-Serag HB, "The association between diabetes and hepatocellular carcinoma : a systematic review of epidemiologic evidence", Clin Gastroenterol Hepatol, 4, pp.369~380 (2006)
9. Park JW, "Global patterns of hepatocellular carcinoma management from diagnosis to death : the BRIDGE study", Liver Int, 35, pp.2155~2166 (2015)
10. Ross RK, "Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma", Lancet, 339, pp.943~946 (1992)
11. Teng MLP, "The growing threat of non-alcoholic fatty liver disease-related hepatocellular carcinoma", Hepatobiliary Surg Nutr, 11, pp.735~737 (2022)
12. Tan DJH, "Global burden of liver cancer in males and females : changing etiological basis and the growing contribution of NASH", Hepatology, 77, pp.1150~1163 (2023)
13. Huang DQ, "Changing global epidemiology of liver cancer from 2010to 2019 : NASH is the fastest growing cause of liver cancer", Cell Metab, 34, pp.969~977 (2022)
14. Huang DQ, "Global epidemiology of NAFLD-related HCC : trends, predictions, risk factors and prevention", Nat Rev Gastroenterol Hepatol, 18, pp.223~238 (2021)
15. Welzel TM, "Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States", Am J Gastroenterol, 108, pp.1314~1321 (2013)
16. Yang JD, "Recent trends in the epidemiology of hepatocellular carcinoma in olmsted county, minnesota : a US population-based study", J Clin Gastroenterol, 51, pp.742~748 (2017)
17. Tan DJH, "Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma : a systematic review and meta-analysis", Lancet Oncol, 23, pp.521~530 (2022)
18. Gomaa AI, "Hepatocellular carcinoma : epidemiology, risk factors and pathogenesis", World J Gastroenterol, 14, pp.4300~4308 (2008)
19. Kim GA, "Metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatotic liver disease with increased alcohol intake increase the risk of developing hepatocellular carcinoma and incident or decompensated cirrhosis : a Korean nationwide study", Liver Cancer (2023)[DOI]
20. Rinella ME, "A multisociety Delphi consensus statement on new fatty liver disease nomenclature", J Hepatol, 79, pp.1542~1556 (2023)
21. Seong SC, "Data resource profile : the national health information database of the National Health Insurance Service in South Korea", Int J Epidemiol, 46, pp.799~800 (2017)
22. Koehler EM, "External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in a populationbased study", Clin Gastroenterol Hepatol, 11, pp.1201~1204 (2013)
23. Yang BL, "External validation of fatty liver index for identifying ultrasonographic fatty liver in a large-scale cross-sectional study in Taiwan", PLoS One, 10, pp.e0120443~ (2015)
24. Jeong S, "Validity of fatty liver prediction scores for diagnosis of fatty liver by Fibroscan", Hepatobiliary Pancreat Dis Int, 23, pp.353~360 (2024)
25. Moon JH, "Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease : a nationwide cohort study", EClinicalMedicine, 65, pp.102292~ (2023)
26. Bedogni G, "The fatty liver index : a simple and accurate predictor of hepatic steatosis in the general population", BMC Gastroenterol, 6, pp.33~ (2006)
27. Yang YS, "Obesity fact sheet in Korea, 2021 : trends in obesity prevalence and obesity-related comorbidity incidence stratified by age from 2009 to 2019", J Obes Metab Syndr, 31, pp.169~177 (2022)
28. Kim K, "Association of fasting serum glucose level and type 2 diabetes with hepatocellular carcinoma in men with chronic hepatitis B infection : a large cohort study", Eur J Cancer, 102, pp.103~113 (2018)
29. Harrison SA, "Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease", Gut, 57, pp.1441~1447 (2008)
30. Grgurevic I, "Hepatocellular carcinoma in non-alcoholic fatty liver disease : from epidemiology to diagnostic approach", Cancers(Basel), 13, pp.5844~ (2021)
31. Kim SK, "TERT promoter mutations and chromosome 8p loss are characteristic of nonalcoholic fatty liver disease-related hepatocellular carcinoma", Int J Cancer, 139, pp.2512~2518 (2016)
32. Hagiwara S, "Accumulation of genetic and epigenetic alterations in the background liver and emergence of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease", Cells, 10, pp.3257~ (2021)
33. Loomba R, "AGA clinical practice update on screening and surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease : expert review", Gastroenterology, 158, pp.1822~1830 (2020)
34. Vanni E, "Obesity and liver cancer", Clin Liver Dis, 18, pp.191~203 (2014)
35. Marengo A, "Liver cancer : connections with obesity, fatty liver, and cirrhosis", Annu Rev Med, 67, pp.103~117 (2016)
36. Park EJ, "Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression", Cell, 140, pp.197~208 (2010)
37. Marra F, "Adipokines in liver diseases", Hepatology, 50, pp.957~969 (2009)
38. Zámbó V, "Lipotoxicity in the liver", World J Hepatol, 5, pp.550~557 (2013)
39. Masson N, "Hypoxia signaling pathways in cancer metabolism : the importance of co-selecting interconnected physiological pathways", Cancer Metab, 2, pp.3~ (2014)
40. Peleman C, "Emerging role of ferroptosis in metabolic dysfunction-associated steatotic liver disease : revisiting hepatic lipid peroxidation", EBioMedicine, 102, pp.105088~ (2024)
41. Yoshimoto S, "Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome", Nature, 499, pp.97~101 (2013)
42. Dongiovanni P, "Hepatocellular carcinoma in nonalcoholic fatty liver : role of environmental and genetic factors", World J Gastroenterol, 20, pp.12945~12955 (2014)
43. Behary J, "Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma", Nat Commun, 12, pp.187~ (2021)
44. Pfister D, "NASH limits anti-tumour surveillance in immunotherapy-treated HCC", Nature, 592, pp.450~456 (2021)

관련 논문AI추천